meplazumab / Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University |
NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19 |
|
|
| Withdrawn | 3 | 1320 | RoW | Meplazumab foe injection, Normal saline | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | COVID-19 | 09/23 | 12/23 | | |
NCT05813587: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19 |
|
|
| Completed | 3 | 121 | RoW | Meplazumab for injection, Normal saline | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Post-COVID-19 | 09/23 | 10/23 | | |
NCT05679479: Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19 |
|
|
| Completed | 3 | 108 | RoW | Meplazumab for injection, Normal saline | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | COVID-19 | 01/24 | 04/24 | | |
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19 |
|
|
| Completed | 2/3 | 150 | RoW | Meplazumab for Injection, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Covid19 | 09/22 | 10/22 | | |
NCT04586153: Study to Assess the Effect of Meplazumab on COVID-19 |
|
|
| Completed | 2/3 | 174 | RoW | Meplazumab for Injection, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | COVID-19 | 12/22 | 12/22 | | |
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum |
|
|
| Active, not recruiting | 2 | 60 | RoW | Meplazumab for Injection | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Malaria | 08/25 | 10/25 | | |
| Recruiting | 2 | 18 | RoW | Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline | Xijing Hospital | Coronary Artery Disease | 09/25 | 03/26 | | |
NCT04327310: Clinical Study of Meplazumab to Treat With Malaria |
|
|
| Withdrawn | 1 | 112 | NA | Meplazumab for Injection, Meplazumab, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Malaria (Plasmodium Falciparum) | 12/23 | 03/24 | | |
metuzumab / Jiangsu Pacific Meinuoke Biopharmaceutical |
DynastyBreast01, CTR20233403: A Phase III, Multicenter, Open-label, Randomized Controlled Study to Evaluate DB-1303 Versus Enmetuzumab (T-DM1) in Patients With HER2-Positive Unresectable/Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxanes (Dynasty-Breast01) |
|
|
| Ongoing | 3 | 224 | China | Kadcyla (ado-trastuzumab emtansine) - Roche, BNT323 - BioNTech | Yingen Biopharmaceutical (Suzhou) Co., Ltd | HER2-positive unresectable/metastatic breast cancer | | | | |
CAR-TG / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
CAR-TH / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
ADC-1 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC003 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC004 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC005 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC006 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC007 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
PMC008 / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
anti-RANKL monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
tocilizumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |
adalimumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical |
No trials found |